ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Waterjet Ablation Therapy for Treating BPO in Patients with Small-to Medium-size Glands
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 154656" data-attributes="member: 13851"><p><span style="font-size: 26px"><strong>Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry.</strong></span></p><p>Misrai V, Rijo E, Zorn KC, Barry-Delongchamps N, Descazeaud A.</p><p></p><p></p><p><strong>Background:</strong> <em>Aquablation has emerged as a novel ablative therapy combining image guidance and robotics for targeted waterjet adenoma resection.</em></p><p></p><p><strong>Objective:</strong> <em>To describe a standardized technique of aquablation in the treatment of benign prostatic obstruction (BPO), and to report the perioperative and 1-yr functional outcomes obtained by multiple surgeons with no previous experience of the technique.</em></p><p></p><p><strong>Design, setting, and participants:</strong> <em>Between September 2017 and January 2018, patients referred to three different urological centers for BPO surgical management were prospectively enrolled to undergo an aquablation procedure.</em></p><p></p><p><strong>Surgical procedure:</strong> <em>Aquablation was performed using the Aquabeam system (Procept BioRobotics, Redwood Shores, CA, USA) that combines transrectal prostatic image guidance and robotics bespoke tissue resection with a high-pressure saline jet. The surgeon defines the area of treatment, and the resection is executed automatically.</em></p><p></p><p><strong>Measurements:</strong> <em>The primary endpoint was the change in total International Prostate Symptom Score (IPSS) score at 6 and 12 mo. Functional outcomes were assessed at 1, 3, 6, and 12 mo with IPSS, International Index of Erectile Function (IIEF)-15, Sexual Health Inventory for Men, and Male Sexual Health Questionnaire questionnaires and uroflowmetry.</em></p><p></p><p><strong>Results and limitations: </strong><em>Thirty patients were enrolled in the study. The median operative time and resection time were 30.5 (24–35) and 4 (3.1–4.9) min, respectively. The median catheterization time was 43 (23–49) h. The median hospitalization stay was 2 (2–4) d. The IPSS score improved to 3 (1–6) at the 6 mo, with a mean change of 15.6 points (95% confidence interval 13–18.2). IPSS improvements persisted at month 12. The maximum urinary flow rate improved to 20.4 (17–26) ml/s at 12 mo. The 6-mo rates of Clavien-Dindo grade 2 and 3 events were 13.3%. There were no reports of incontinence or de novo erectile dysfunction. Postoperative de novo ejaculatory dysfunction was observed in 26.7% of patients</em></p><p></p><p><strong>Conclusions:</strong> <strong><span style="color: rgb(184, 49, 47)"><em>This clinical registry confirmed that aquablation was feasible, safe, and effective, and provided immediate good functional results and similar outcomes to those of prior studies despite the lack of surgeons’ previous experience with the technique. </em></span></strong></p><p><strong></strong></p><p><strong>Patient summary:<span style="color: rgb(44, 130, 201)"> <em>Aquablation is feasible, safe, and reproducible with promising outcomes for treating benign prostatic enlargement.</em></span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 154656, member: 13851"] [SIZE=26px][B]Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry.[/B][/SIZE] Misrai V, Rijo E, Zorn KC, Barry-Delongchamps N, Descazeaud A. [B]Background:[/B] [I]Aquablation has emerged as a novel ablative therapy combining image guidance and robotics for targeted waterjet adenoma resection.[/I] [B]Objective:[/B] [I]To describe a standardized technique of aquablation in the treatment of benign prostatic obstruction (BPO), and to report the perioperative and 1-yr functional outcomes obtained by multiple surgeons with no previous experience of the technique.[/I] [B]Design, setting, and participants:[/B] [I]Between September 2017 and January 2018, patients referred to three different urological centers for BPO surgical management were prospectively enrolled to undergo an aquablation procedure.[/I] [B]Surgical procedure:[/B] [I]Aquablation was performed using the Aquabeam system (Procept BioRobotics, Redwood Shores, CA, USA) that combines transrectal prostatic image guidance and robotics bespoke tissue resection with a high-pressure saline jet. The surgeon defines the area of treatment, and the resection is executed automatically.[/I] [B]Measurements:[/B] [I]The primary endpoint was the change in total International Prostate Symptom Score (IPSS) score at 6 and 12 mo. Functional outcomes were assessed at 1, 3, 6, and 12 mo with IPSS, International Index of Erectile Function (IIEF)-15, Sexual Health Inventory for Men, and Male Sexual Health Questionnaire questionnaires and uroflowmetry.[/I] [B]Results and limitations: [/B][I]Thirty patients were enrolled in the study. The median operative time and resection time were 30.5 (24–35) and 4 (3.1–4.9) min, respectively. The median catheterization time was 43 (23–49) h. The median hospitalization stay was 2 (2–4) d. The IPSS score improved to 3 (1–6) at the 6 mo, with a mean change of 15.6 points (95% confidence interval 13–18.2). IPSS improvements persisted at month 12. The maximum urinary flow rate improved to 20.4 (17–26) ml/s at 12 mo. The 6-mo rates of Clavien-Dindo grade 2 and 3 events were 13.3%. There were no reports of incontinence or de novo erectile dysfunction. Postoperative de novo ejaculatory dysfunction was observed in 26.7% of patients[/I] [B]Conclusions:[/B] [B][COLOR=rgb(184, 49, 47)][I]This clinical registry confirmed that aquablation was feasible, safe, and effective, and provided immediate good functional results and similar outcomes to those of prior studies despite the lack of surgeons’ previous experience with the technique. [/I][/COLOR] Patient summary:[COLOR=rgb(44, 130, 201)] [I]Aquablation is feasible, safe, and reproducible with promising outcomes for treating benign prostatic enlargement.[/I][/COLOR][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Waterjet Ablation Therapy for Treating BPO in Patients with Small-to Medium-size Glands
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top